female-lab-assistant-using-laptop-for-data-entry-and-in-other-hand-holding-test-tube-with-blood-sample-while-sitting-in-laboratory female-lab-assistant-using-laptop-for-data-entry-and-in-other-hand-holding-test-tube-with-blood-sample-while-sitting-in-laboratory

Meet the
Expert Session

Banner Arrow

Understanding the Impact of Humira Biosimilars on Market Access

Humira, one of the top-selling drugs in the US, is about to see a slew of competition with seven adalimumab biosimilars approved and set to launch in 2023. We’ll explore how we can expect the market to react and how factors such as launch timing, interchangeability, and contracting will shape the immunology landscape.

Summary:

  • How have payers changed their strategy in anticipation of the availability of adalimumab biosimilars next year?
  • What is the payer perception of the adalimumab biosimilars and of the staggered launches of these products throughout 2023?
  • Between Humira and the biosimilars, how many do payers anticipate they will cover and what factors are going to inform these decisions?
  • What are the considerations for patients who are currently being prescribed Humira?

Download the recording for MMIT’s Meet the Expert session today!



Our Expert

headshot-steve-callahan

Steve Callahan
Sr. Manager, Market Research

Steve Callahan initially got his start conducting research in biology but transitioned his focus to Market Access as a consultant at firms such as Compass Strategic Consulting, Certara Evidence and Access, and IQVIA, and most recently as a senior manager leading market research for MMIT. Steve has conducted extensive research and has led a variety of projects within immunology and with biosimilars. Steve earned his B.S. in biology at Fairfield University, his M.S. in biology at Southern Connecticut State University, and his M.B.A. at the University of Connecticut.